Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Paul Jules Van Houtte

Can We Omit Radiotherapy in Case of Brain Metastases for Patients With Mutant EGFR Lung Adenocarcinoma?

Translational Lung Cancer Research

Oncology

2017

English

Related publications

P1.01-100 Concurrent Brain Radiotherapy and EGFR-TKI Have Better Survival Benefits in Patients With Brain Metastases From EGFR-Mutant NSCLC

Journal of Thoracic Oncology

English

Targeted Sequencing and Intracranial Outcomes of Patients With Lung Adenocarcinoma Brain Metastases Treated With Radiotherapy

English

Erlotinib in Symptomatic Brain Metastases From a Lung Adenocarcinoma With a Sensitizing EGFR Mutation

Journal of Thoracic Oncology

English

Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-Del-Egfr Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature

Frontiers in Oncology

Cancer Research

Oncology

2017

English

MA08.06 Outcomes Among Patients With EGFR-Mutant Metastatic NSCLC With and Without Brain Metastases

Journal of Thoracic Oncology

English

Efficacy and Safety of Icotinib in Patients With Brain Metastases From Lung Adenocarcinoma

OncoTargets and Therapy

Oncology

Pharmacology

2016

English

Correction To: Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined With Chemotherapy Delay Brain Metastasis in Patients With EGFR‑Mutant Lung Adenocarcinoma

English

MA08.03 EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients With Brain Metastases: A Meta-Analysis

Journal of Thoracic Oncology

English

Cranial Irradiation for Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Paul Jules Van Houtte

Can We Omit Radiotherapy in Case of Brain Metastases for Patients With Mutant EGFR Lung Adenocarcinoma?

Related publications

P1.01-100 Concurrent Brain Radiotherapy and EGFR-TKI Have Better Survival Benefits in Patients With Brain Metastases From EGFR-Mutant NSCLC

Targeted Sequencing and Intracranial Outcomes of Patients With Lung Adenocarcinoma Brain Metastases Treated With Radiotherapy

Erlotinib in Symptomatic Brain Metastases From a Lung Adenocarcinoma With a Sensitizing EGFR Mutation

Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-Del-Egfr Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature

MA08.06 Outcomes Among Patients With EGFR-Mutant Metastatic NSCLC With and Without Brain Metastases

Efficacy and Safety of Icotinib in Patients With Brain Metastases From Lung Adenocarcinoma

Correction To: Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined With Chemotherapy Delay Brain Metastasis in Patients With EGFR‑Mutant Lung Adenocarcinoma

MA08.03 EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients With Brain Metastases: A Meta-Analysis

Cranial Irradiation for Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors